144 related articles for article (PubMed ID: 38086333)
21. Retinoblastoma co-repressor 1 (RB) and cyclin-dependent kinase inhibitor (CDKN) as a multi-gene panel for differentiating pulmonary from non-pulmonary origin in metastatic neuroendocrine carcinomas.
Krishnamurthy K; Cusnir M; Schwartz M; Sriganeshan V; Poppiti RJ
Pathol Res Pract; 2020 Sep; 216(9):153051. PubMed ID: 32825935
[TBL] [Abstract][Full Text] [Related]
22. An integrated cellular and molecular model of gastric neuroendocrine cancer evolution highlights therapeutic targets.
Griger J; Widholz SA; Jesinghaus M; de Andrade Krätzig N; Lange S; Engleitner T; Montero JJ; Zhigalova E; Öllinger R; Suresh V; Winkler W; Lier S; Baranov O; Trozzo R; Ben Khaled N; Chakraborty S; Yu J; Konukiewitz B; Steiger K; Pfarr N; Rajput A; Sailer D; Keller G; Schirmacher P; Röcken C; Fagerstedt KW; Mayerle J; Schmidt-Supprian M; Schneider G; Weichert W; Calado DP; Sommermann T; Klöppel G; Rajewsky K; Saur D; Rad R
Cancer Cell; 2023 Jul; 41(7):1327-1344.e10. PubMed ID: 37352862
[TBL] [Abstract][Full Text] [Related]
23. Neuroendocrine Cancer, Therapeutic Strategies in G3 Cancers.
Rinke A; Gress TM
Digestion; 2017; 95(2):109-114. PubMed ID: 28161703
[TBL] [Abstract][Full Text] [Related]
24. Analysis of p53, K-ras-2, and C-raf-1 in pulmonary neuroendocrine tumors. Correlation with histological subtype and clinical outcome.
Przygodzki RM; Finkelstein SD; Langer JC; Swalsky PA; Fishback N; Bakker A; Guinee DG; Koss M; Travis WD
Am J Pathol; 1996 May; 148(5):1531-41. PubMed ID: 8623922
[TBL] [Abstract][Full Text] [Related]
25. Nordic 2023 guidelines for the diagnosis and treatment of lung neuroendocrine neoplasms.
Dam G; Grønbæk H; Sundlöv A; Botling J; Sundin A; Petersen RH; Welin S; Evensen ET; Sorbye H; Tabaksblat E; Arveschoug AK; Mortensen J; Kjaer A; Knigge U; Tiensuu Janson E; Langer SW
Acta Oncol; 2023 May; 62(5):431-437. PubMed ID: 37194281
[TBL] [Abstract][Full Text] [Related]
26. Molecular profiling and target actionability for precision medicine in neuroendocrine neoplasms: real-world data.
Boilève A; Faron M; Fodil-Cherif S; Bayle A; Lamartina L; Planchard D; Tselikas L; Kanaan C; Scoazec JY; Ducreux M; Italiano A; Baudin E; Hadoux J
Eur J Cancer; 2023 Jun; 186():122-132. PubMed ID: 37062210
[TBL] [Abstract][Full Text] [Related]
27. Genomics of High-Grade Neuroendocrine Neoplasms: Well-Differentiated Neuroendocrine Tumor with High-Grade Features (G3 NET) and Neuroendocrine Carcinomas (NEC) of Various Anatomic Sites.
Uccella S; La Rosa S; Metovic J; Marchiori D; Scoazec JY; Volante M; Mete O; Papotti M
Endocr Pathol; 2021 Mar; 32(1):192-210. PubMed ID: 33433884
[TBL] [Abstract][Full Text] [Related]
28. Comparison of Metastatic Patterns Among Neuroendocrine Tumors, Neuroendocrine Carcinomas, and Nonneuroendocrine Carcinomas of Various Primary Organs.
Park HK; Kwon GY
J Korean Med Sci; 2023 Mar; 38(11):e85. PubMed ID: 36942393
[TBL] [Abstract][Full Text] [Related]
29. Thymoquinone Plus Immunotherapy in Extra-Pulmonary Neuroendocrine Carcinoma: Case Series for a Novel Combination.
Mohamed A; Azmi AS; Asa SL; Tirumani SH; Mahipal A; Cjakrabarti S; Bajor D; Selfridge JE; Kaseb AO
Curr Oncol; 2022 Nov; 29(11):9018-9030. PubMed ID: 36421360
[TBL] [Abstract][Full Text] [Related]
30. Molecular Pathology of Well-Differentiated Pulmonary and Thymic Neuroendocrine Tumors: What Do Pathologists Need to Know?
Volante M; Mete O; Pelosi G; Roden AC; Speel EJM; Uccella S
Endocr Pathol; 2021 Mar; 32(1):154-168. PubMed ID: 33641055
[TBL] [Abstract][Full Text] [Related]
31. Utility of secretagogin as a marker for the diagnosis of lung neuroendocrine carcinoma.
Baykara Y; Xiao Y; Yang D; Yakirevich E; Maleki S; Garcia-Moliner M; Wang LJ; Huang CK; Lu S
Virchows Arch; 2022 Jul; 481(1):31-39. PubMed ID: 35357570
[TBL] [Abstract][Full Text] [Related]
32. Molecular Classification of Extrapulmonary Neuroendocrine Carcinomas With Emphasis on POU2F3-positive Tuft Cell Carcinoma.
Koh J; Kim H; Moon KC; Lee C; Lee K; Ryu HS; Jung KC; Jeon YK
Am J Surg Pathol; 2023 Feb; 47(2):183-193. PubMed ID: 36253891
[TBL] [Abstract][Full Text] [Related]
33. Complexin-2 (CPLX2) as a potential prognostic biomarker in human lung high grade neuroendocrine tumors.
Komatsu H; Kakehashi A; Nishiyama N; Izumi N; Mizuguchi S; Yamano S; Inoue H; Hanada S; Chung K; Wei M; Suehiro S; Wanibuchi H
Cancer Biomark; 2013; 13(3):171-80. PubMed ID: 23912489
[TBL] [Abstract][Full Text] [Related]
34. Epidemiological analysis of lung and mediastinal neuroendocrine neoplasms in Japan based on the national database.
Matsuoka S; Koizumi T; Otsuki K; Tanaka Y; Kanda S; Ide S; Mishima S; Takeda T; Miura K; Eguchi T; Hamanaka K; Shimizu K
Cancer Epidemiol; 2022 Apr; 77():102116. PubMed ID: 35144127
[TBL] [Abstract][Full Text] [Related]
35. The treatment of undifferentiated neuroendocrine tumors.
Mitry E; Rougier P
Crit Rev Oncol Hematol; 2001 Jan; 37(1):47-51. PubMed ID: 11164718
[TBL] [Abstract][Full Text] [Related]
36. Survival outcomes and incidence of brain recurrence in high-grade neuroendocrine carcinomas of the lung: Implications for clinical practice.
Metro G; Ricciuti B; Chiari R; Baretti M; Falcinelli L; Giannarelli D; Sidoni A; Mountzios G; Crinò L; Bellezza G; Rebonato A; Ferolla P; Toschi L
Lung Cancer; 2016 May; 95():82-7. PubMed ID: 27040856
[TBL] [Abstract][Full Text] [Related]
37. Biology and evolution of poorly differentiated neuroendocrine tumors.
Rickman DS; Beltran H; Demichelis F; Rubin MA
Nat Med; 2017 Jun; 23(6):1-10. PubMed ID: 28586335
[TBL] [Abstract][Full Text] [Related]
38. Lung Neuroendocrine Tumors: How Does Molecular Profiling Help?
Sun TY; Hendifar A; Padda SK
Curr Oncol Rep; 2022 Jul; 24(7):819-824. PubMed ID: 35305210
[TBL] [Abstract][Full Text] [Related]
39. Spotlight on Small-Cell Lung Cancer and Other Lung Neuroendocrine Neoplasms.
Fernandez-Cuesta L; Sexton-Oates A; Bayat L; Foll M; Lau SCM; Leal T
Am Soc Clin Oncol Educ Book; 2023 May; 43():e390794. PubMed ID: 37229617
[TBL] [Abstract][Full Text] [Related]
40. Pulmonary large cell neuroendocrine carcinoma with adenocarcinoma-like features: napsin A expression and genomic alterations.
Rekhtman N; Pietanza CM; Sabari J; Montecalvo J; Wang H; Habeeb O; Kadota K; Adusumilli P; Rudin CM; Ladanyi M; Travis WD; Joubert P
Mod Pathol; 2018 Jan; 31(1):111-121. PubMed ID: 28884744
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
